Back HIV/AIDS

HIV / AIDS

No New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities

No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.

alt

IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women

Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.

alt

CDC Continues to Recommend Annual HIV Testing for Gay Men

The U.S. Centers for Disease Control and Prevention (CDC) recently reaffirmed its recommendation that sexually active gay and bisexual men should undergo at least annual HIV screening, according to a report in the August 11 edition of the CDC's Morbidity and Mortality Weekly Report. However, some local providers advise more frequent HIV and sexually transmitted infection tests.

alt

IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

San Francisco Annual Report Shows Continued Drop in HIV Infections

The San Francisco Department of Public Health has released its HIV Epidemiology Annual Report for 2016, showing that the number of new infections continues to decline, with decreases seen across demographic groups. Homeless people, however, have higher rates of infection and poorer treatment outcomes.

alt

IAS 2017: Who Are Trans Women Acquiring HIV From?

There is a lot we don't know about trans women's HIV risk, why they are so vulnerable to HIV, and who trans women are acquiring HIV from. A study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) attempted to answer these questions, but in the process uncovered another mystery: is there a hidden population of heterosexual men who have sex with trans women and who are themselves at high risk of acquiring and transmitting HIV? One thing the study did make clear, however, is that a lot of HIV infections among trans women may be due to injecting drugs rather than sex.

alt

IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment

A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt